These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22386472)

  • 1. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain.
    Rowbotham MC; Arslanian A; Nothaft W; Duan RW; Best AE; Pritchett Y; Zhou Q; Stacey BR
    Pain; 2012 Apr; 153(4):862-868. PubMed ID: 22386472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain.
    Rowbotham MC; Duan RW; Thomas J; Nothaft W; Backonja MM
    Pain; 2009 Dec; 146(3):245-252. PubMed ID: 19632048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.
    Apostol G; Abi-Saab W; Kratochvil CJ; Adler LA; Robieson WZ; Gault LM; Pritchett YL; Feifel D; Collins MA; Saltarelli MD
    Psychopharmacology (Berl); 2012 Feb; 219(3):715-25. PubMed ID: 21748252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
    Bain EE; Apostol G; Sangal RB; Robieson WZ; McNeill DL; Abi-Saab WM; Saltarelli MD
    J Clin Psychiatry; 2012 Jun; 73(6):783-9. PubMed ID: 22795204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
    Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
    Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
    Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
    Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
    Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
    Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.
    Bain EE; Robieson W; Pritchett Y; Garimella T; Abi-Saab W; Apostol G; McGough JJ; Saltarelli MD
    Neuropsychopharmacology; 2013 Feb; 38(3):405-13. PubMed ID: 23032073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
    Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
    Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population analyses of efficacy and safety of ABT-594 in subjects with diabetic peripheral neuropathic pain.
    Dutta S; Hosmane BS; Awni WM
    AAPS J; 2012 Jun; 14(2):168-75. PubMed ID: 22328206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
    Raskin J; Pritchett YL; Wang F; D'Souza DN; Waninger AL; Iyengar S; Wernicke JF
    Pain Med; 2005; 6(5):346-56. PubMed ID: 16266355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain.
    Ziegler D; Duan WR; An G; Thomas JW; Nothaft W
    Pain; 2015 Oct; 156(10):2013-2020. PubMed ID: 26067585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine vs. placebo in patients with painful diabetic neuropathy.
    Goldstein DJ; Lu Y; Detke MJ; Lee TC; Iyengar S
    Pain; 2005 Jul; 116(1-2):109-18. PubMed ID: 15927394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients.
    Wasan AD; Ossanna MJ; Raskin J; Wernicke JF; Robinson MJ; Hall JA; Edwards SE; Lipsius S; Meyers AL; McCarberg BH
    Curr Drug Saf; 2009 Jan; 4(1):22-9. PubMed ID: 19149522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies.
    Kajdasz DK; Iyengar S; Desaiah D; Backonja MM; Farrar JT; Fishbain DA; Jensen TS; Rowbotham MC; Sang CN; Ziegler D; McQuay HJ
    Clin Ther; 2007; 29 Suppl():2536-46. PubMed ID: 18164920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.
    Armstrong DG; Chappell AS; Le TK; Kajdasz DK; Backonja M; D'Souza DN; Russell JM
    Pain Med; 2007; 8(5):410-8. PubMed ID: 17661854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594.
    Munro G; Dyhr H; Grunnet M
    Neuropharmacology; 2010 Sep; 59(3):208-17. PubMed ID: 20562022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
    Boyle J; Eriksson ME; Gribble L; Gouni R; Johnsen S; Coppini DV; Kerr D
    Diabetes Care; 2012 Dec; 35(12):2451-8. PubMed ID: 22991449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.